Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial

2019 ◽  
Vol 38 (12) ◽  
pp. 3367-3374 ◽  
Author(s):  
Seyed Mostafa Nachvak ◽  
Beitollah Alipour ◽  
Aida Malek Mahdavi ◽  
Mir Amir Aghdashi ◽  
Hadi Abdollahzad ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trial ◽  
Matrix Metalloproteinases ◽  
Coenzyme Q10 ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Das 28 ◽  
Coenzyme Q10 Supplementation

scholarly journals Effects of coenzyme Q10 supplementation on oxidative stress and antioxidant enzyme activity in glazers with occupational cadmium exposure: A randomized, double-blind, placebo-controlled crossover clinical trial

2018 ◽  
Vol 35 (1) ◽  
pp. 32-42 ◽  
Author(s):  
Maryam Hormozi ◽  
Ramazan Mirzaei ◽  
Alireza Nakhaee ◽  
Abolfazl payandeh ◽  
Shahrokh Izadi ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Clinical Trial ◽  
Antioxidant Enzymes ◽  
Coenzyme Q10 ◽  
Dietary Intervention ◽  
Oxidative Stress Marker ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Enzymes Activity ◽  
Coenzyme Q10 Supplementation

Recently, there is a growing interest for the use of antioxidants as a preventive agent against cadmium (Cd) intoxication. The current study aimed to investigate the effects of dietary coenzyme Q10 supplementation on oxidative stress and antioxidant enzymes activity in Cd-exposed glazers. In a randomized, double-blind, placebo-controlled 2-month crossover clinical trial, coenzyme Q10 (60 mg twice daily) or placebo was administrated to 40 male glazers occupationally exposed to Cd. The subjects were randomly assigned to the placebo and coenzyme Q10 groups ( n = 20 in each group). Total antioxidant capacity (TAC), superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) as well as malondialdehyde (MDA) in the serum of glazers were measured at baseline and at the end of both intervention phases. The primary outcomes were the changes in serum levels of MDA, TAC and the activities of SOD, CAT, and GPx during administration with coenzyme Q10 versus placebo. Compared with placebo, treatment to coenzyme Q10 was associated with a significant reduction in serum MDA levels ( p < 0.001) While, there was no significant effect on the serum TAC levels ( p = 0.096). Also, the activity antioxidant enzymes of SOD ( p < 0.001) and GPx ( p = 0.003) were significantly higher and the CAT activity ( p < 0.001) was lower after 2-month coenzyme Q10 administration compared with placebo. Data demonstrated that coenzyme Q10 supplementation at a dose of 60 mg (twice daily) is effective in reducing oxidative stress marker level (MDA) and improving antioxidant enzymes activity in glazers exposed to Cd. However, further research is needed to assess coenzyme Q10 as a possible dietary intervention in Cd-exposed workers. Trial Registration: Iranian Registry of Clinical Trials Registration Number: IRCT2016061228407N1 ( www.who.int/ictrp/network/irct/en/ ).

The Effect of Coenzyme Q10 Supplementation on Pro-Inflammatory Factors and Adiponectin in Mildly Hypertensive Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

2015 ◽  
Vol 85 (3-4) ◽  
pp. 156-164 ◽  
Author(s):  
Nasim Bagheri Nesami ◽  
Hassan Mozaffari-Khosravi ◽  
Azadeh Najarzadeh ◽  
Ebrahim Salehifar
Keyword(s):  
Coenzyme Q10 ◽  
Inflammatory Factors ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Double Blind Placebo ◽  
Tnf Α ◽  
The Mean ◽  
Hs Crp ◽  
Coenzyme Q10 Supplementation

Abstract. Introduction: There is considerable evidence that hypertension may increase the levels of cytokines via endothelial stimulation and may stimulate inflammatory reactions. The purpose of this study was to evaluate the effect of oral coenzyme Q10 supplementation on pro-inflammatory factors and adiponectin in mildly hypertensive patients. Methods: This 12-week randomized, double-blind, placebo-controlled clinical trial was carried out during 2012 - 2013 in Yazd. Sixty mildly hypertensive patients were randomly divided into two groups: placebo (PG, n = 30) and coenzyme Q10 (QG, n = 30). The QG was given 1 capsule containing 100 mg Q10 per day. The PG was given 1 capsule of the same size and color as the Q10 capsules, but it contained 100 mg of lactose. Plasma pro-inflammatory factors (IL6, IL2, and TNF-α), adiponectin, and hs-CRP were determined before and after the intervention. Results: The mean enhancement in adiponectin of QG was significantly higher than PG (from 21.1 ± 14.5 to 24.2 ± 15.5 ng/ml, P = 0.04). Significant declines in the median of IL6 (from 23 to 16 pg/ml, P = 0.001) and in the mean of hs-CRP were also observed in QG after intervention (from 3.53 ± 3.36 to 2.62 ± 2.51 mg/L, P = 0.03). In the two groups, no significant statistical changes were seen in the median of TNF-α and IL2. Conclusion: Daily supplementation of 100 mg coenzyme Q10 can be effective in decreasing some pro-inflammatory factors, such as IL6 and hs-CRP, and in increasing adiponectin.

Sign in / Sign up

Export Citation Format

Share Document